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1. Introduction
Leishmaniasias is a complex of diseases caused by intracellular protozoan parasites that belong
to the genus Leishmania (class: Kinetoplastida; order: Trypanosomatidae), for which there are
more than 20 different species, and is transmitted by the bite of female phlebotomine sand flies
(order: Diptera; family: Psychodidae; subfamily: Phlebotominae). Various species of phlebot‐
omine sand flies of the genus Phlebotomus are responsible for transmission of leishmaniasis in
the Old World, and of the genus Lutzomyia in the New World [1]. Leishmania parasite has a
digenetic life-cycle alternating between a mammalian host and insect vectors, phlebotomine
sand flies, which are small (1.5-2 mm body length) insects mainly found in tropical and
subtropical regions. Leishmania lives extracellularly as flagellated promastigotes in the gut and
salivary glands of the sand fly vector, and intracellularly as amastigotes in the vertebrate host
macrophages. Leishmania promastigotes, transmitted to mammalian skin by the bite of a female
phlebotomine sand fly, invade human macrophages as the main host for the parasites, where
Leishmania transforms into amastigotes and replicate intracellularly. Leishmaniasis represents
a major international health problem, has a high morbidity and mortality rate, and is classified
as an emerging and uncontrolled disease by the World Health Organization (WHO). The
disease burden of leishmaniasis is high, with about 350 million people in 98 countries consid‐
ered at risk. Among parasitic diseases, leishmaniasis accounts for the second highest burden
of disease after malaria, with a loss of about 2.4 million disability-adjusted life years (DALYs)
[2, 3]. There are an estimated 1.5-2 million new cases per year, with 1.5 million cases of self-
healing, but disfiguring, (muco-)cutaneous leishmaniasis, and 500,000 cases of life-threatening
visceral leishmaniasis [2, 3]. However, more than 90% of the world’s cases of visceral leish‐
maniasis are in India, Bangladesh, Nepal, Sudan, and Brazil. Some species tend to cause
cutaneous leishmaniasis (e.g., L. major and L.tropica), whereas others lead to cause visceral
leishmaniasis (e.g., L. infantum and L. donovani). Leishmaniases are usually classified based on
the clinical manifestations, leading to three major clinical forms, namely:
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• Cutaneous leishmaniasis. It is the most common form of the disease, leading to a skin sore
at the bite site, which erupts weeks to months after the person affected is bitten by sand flies,
and then heals in a few months to a year, leaving an unpleasant-looking scar.
• Mucocutaneous leishmaniasis. It occurs predominantly in the New World, starting with
skin ulcers which spread, causing tissue damage and destruction, and certain Leishmania
species migrate to the upper respiratory tract where destruction of the oropharynx and nose
ensues, resulting in extensive midfacial destruction and, occasionally, in death.
• Visceral leishmaniasis. It is classically known as kala-azar, and also referred to as black fever,
and Dumdum fever. It is the most serious and devastating form of the disease, where the
parasites localize to the reticuloendothelial system, rather than to the skin, and migrate to
and affect internal organs (usually spleen, liver, and bone marrow), producing a potentially
lethal widespread systemic disease that is fatal if untreated. Visceral leishmaniasis is
characterized by irregular bouts of fever, weight loss, substantial swelling of the spleen and
liver, fatigue and anemia. The systemic infection of the liver, spleen and bone marrow leads
to hepatomegaly, splenomegaly, lymph node enlargement, thrombocytopenia, and anemia.
Cutaneous leishmaniasis can be further divided into: a) localized (crusted papules or ulcers
occur several weeks to months after sand fly bite inoculation on exposed skin, and lesions
usually heal spontaneously); b) diffuse cutaneous (producing widespread skin lesions which
resemble leprosy, being particularly difficult to treat; and patients cannot mount a cell-
mediated immune response to the Leishmania parasite, developing multiple, widespread
cutaneous papules and nodules); c) recidivans (appearing as a recurrence of lesions at the site
of apparently healed disease years after the original infection; and occurring typically on the
face as an enlarging papule, plaque, or coalescence of papules that heals with central scarring,
leading to facial destruction in some cases); d) post-kala-azar dermal leishmaniasis (a compli‐
cation of visceral leishmaniasis in areas where L. donovani is endemic, and characterized by a
hypopigmented macular, maculopapular, and nodular rash that usually appears 6 months to
1 or more years after apparent cure of visceral leishmaniasis).
Another way to categorize leishmaniasis is based on geographic occurrence. Thus, Old World
leishmaniasis, caused by Leishmania species found in Africa, Asia, the Middle East, and the
Mediterranean, mainly leads to cutaneous or visceral forms of disease; and New World
leishmaniasis, caused by Leishmania species found in endemic regions extending from southern
USA to northern Argentina, mainly in Central and South America, generates cutaneous,
mucocutaneous, and visceral forms of disease. It is interesting to note that distinct forms of
leishmaniasis follow different clinical courses of the disease depending on the geographical
location. Thus, post-kala-azar dermal leishmaniasis heals spontaneously in the majority of
cases in Africa, but rarely in patients in India. This form of leishmaniasis, endemic to India and
Sudan, is considered to have an important role in maintaining and contributing to transmission
of the disease particularly in interepidemic periods of visceral leishmaniasis, acting as a
reservoir for parasites. Post-kala-azar dermal leishmaniasis reflects the immune response of
the individual to the Leishmania organism, and lesions may be numerous and persist for
decades. Most forms of the disease are transmissible from non-human animals to people
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(zoonotic transmission), but some can be spread between humans (anthroponotic transmis‐
sion).
The chemotherapy currently available for the treatment of leishmaniasis is far from satisfactory
and shows a series of problems, including toxicity, adverse side-effects, high costs and
development of drug resistance [2, 4]. Thus, search for new antilesihmanial drugs is urgently
needed.
2. Miltefosine as a new antileishmanial drug
The control of leishmaniasis in the absence of vaccine depends solely on the choice of chemo‐
therapy. Additional complications in the treatment of leishmaniasis include intrinsic species-
specific differences in drug susceptibility [5, 6] as well as differences in drug efficacy between
geographical areas [7], which can reflect the genetic differences between Leishmania parasites
at species and strain levels [8, 9]. The generation of drug resistance is a major concern in the
treatment of leishmaniasis that can be worsened by the rather low number of drugs currently
available in therapy, thus leading to the lack of a putative alternative for a drug to which
resistance has arisen. In this regard, it is well known the increasing resistance against the
widely used pentavalent antimonial compounds in India, where resistance rates have been
shown to be higher than 60% in parts of the state of Bihar, in north-east India [10, 11]. Thus,
search for novel anti-Leishmania drugs is desperately needed. In the last years a new drug has
been included in the clinical arsenal of antileishmanial drugs named miltefosine (hexadecyl‐
phoshocholine) (Figure 1), which is orally administered and is effective against pentavalent
antimonial compound-resistant Leishmania parasites. Following a number of successful clinical
trials ranging from phase I/II to phase IV in the period 1996-2004, miltefosine was registered
as a new antileishmanial drug in India in 2002 [12]. Miltefosine, registered under the trade
name of Impavido®, is the first oral drug in leishmaniasis therapy, having being developed by
Zentaris (Frankfurt, Germany) in close cooperation with WHO/Special Programme for
Research & Training in Tropical Diseases (TDR), and currently being manufactured by Paladin
(Quebec, Canada). The standard miltefosine treatment includes oral administration of 100-150
mg/day, depending on the body weight, for 28 days and is well tolerated, except for mild
gastrointestinal side effects.
Figure 1. Chemical structures of edelfosine and miltefosine.
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Miltefosine treatment leads to high cure rates in visceral leishmaniasis in India (L. donovani;
94% cure) [13]. However, different trials regarding the efficacy of miltefosine against cutaneous
leishmaniasis in Colombia led to distinct outcomes ranging from a 90% cure [14] to an
unsatisfactory cure rate of 69.8% [15]. Sensitivity to miltefosine is known to vary between
Leishmania species [16]. In this regard, L. braziliensis seems to be somewhat refractory to
miltefosine as shown in a number of clinical studies [14, 17-19]. Miltefosine efficacy against
leishmaniasis lesions caused by L. braziliensis, which comprise more than 60% of cutaneous
leishmaniasis in Colombia, fell to 49% [15], and was only 33% in Guatemala [14]. Additional
clinical trials in Brazil showed a miltefosine cure rate of 75% and 71% for the treatment of
cutaneous leishmaniasis caused by L. braziliensis [20] and L. guyanensis [21], respectively. Thus,
these trials have challenged the therapeutical potential of miltefosine for the treatment of
American cutaneous leishmaniasis. Miltefosine treatment has also led to approximately 70%
cure rate for mucosal leishmaniasis due to L. braziliensis in Bolivia [18, 22], 53% for cutaneous
leishmaniasis (33% for L. braziliensis infection, and 60% for L. mexicana infection) in Guatemala
[14, 17, 23], and 63% for L. tropica infection in Afghanistan [23]. The above cure rates contrast
with those reported for the treatment of visceral leishmaniasis (kala-azar) in India [12, 24] and
Bangladesh [25] that were higher than 82%. These data highlight the great variability in the
clinical outcome depending on the geographical area for reasons that are not well understood.
The main toxicity for miltefosine involves gastrointestinal organs in both animal and human
studies. Thus, miltefosine frequently induces gastrointestinal side effects, such as anorexia,
nausea, vomiting and diarrhea, that sometimes lead to drop out from treatment [2, 3, 24]. The
testis and retina have been identified as target organs in rats, but the expected and corre‐
sponding effects and symptoms based on these observations have not been detected in clinical
studies in humans [26]. Miltefosine distributes widely in body organs and is not metabolized
by cytochrome P450 enzymes in vitro. Miltefosine has been found to be embryotoxic and
fetotoxic in rats and rabbits, and teratogenic in rats, but not in rabbits [26]. Thus, miltefosine
is potentially teratogenic, being contraindicated for use during pregnancy, and adequate
contraception is required during treatment and for up to 3 months afterwards in women of
child-bearing age [2, 3, 26]. An additional concern is the rapid in vitro generation of resistance
to miltefosine [27-30] that could limit its clinical use.
Miltefosine is a member of a family of structurally-related compounds collectively known as
synthetic alkylphospholipids (APLs), that target cell membranes and show pleiotropic actions
with multiple biomedical applications in addition to their antitumor effect, which have been
widely studied [31-35]. The advent of miltefosine as a new antileishmanial drug introduces
APLs as putative novel drugs for the treatment of leishmaniasis. In addition, because of the
numerous studies reported on the antitumor action of these compounds, it could be envisaged
that the insight acquired for their antitumor action might be of use in the treatment of leish‐
maniasis.
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3. Alkylphospholipids and leishmaniasis
As stated above miltefosine is a member of a series of synthetic lipids structurally related and
known collectively as APLs, which in turn can be classified in two major categories [31]: a) the
alkyl ether phospholipids (AEPs), widely referred to collectively as alkyl-lysophospholipid
analogs (ALPs), containing ether bonds in the glycerol backbone of the phospholipid, as
exemplified by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3;
edelfosine) (Figure 1); b) and the alkylphosphocholines (APCs), lacking the glycerol backbone
and formed by a simple long-chain alcohol esterified to a phosphobase, as exemplified by
hexadecylphosphocholine (HPC; miltefosine) (Figure 1). All of these APLs show low rates of
metabolism both in vitro and in vivo. APLs were initially shown to elicit actions on the immune
system and to kill cancer cells [31, 33, 35]. The first studies of the antiprotozoal activity of APLs
in the 1980s against Tetrahymena pyriformis [36] and L. donovani [37, 38] were reported soon
after their development as anticancer drugs [39-41]. APLs have been reported to be effective
against different Leishmania species, including L. donovani, L. infantum (Old World)/chagasi
(New World), L. major, L. braziliensis, L. amazonensis, L. mexicana, L. panamensis, L. guyanensis,
L. tropica, L. aethiopica and L. lainsoni [16, 42-44].
In 1987, Croft et al. [38] reported the antiparasitic action of miltefosine against L. donovani
amastigotes. Subsequently, in vivo studies showed the antileishmanial activity of miltefosine
(10-20 mg/kg of body weight/day, orally administered) in mice infected with L. donovani and
L. infantum [45]. Later on, following eight successful clinical trials [12], miltefosine (Impavi‐
do®) became the first oral treatment of visceral leishmaniasis and is the most recent drug to
come to the market for the treatment of this disease.
Within APLs, edelfosine has been considered as the long-standing prototype of these com‐
pounds, and recent evidences have unveiled part of its mechanism of action as a promising
antitumor drug. Another APL named perifosine, a miltefosine analog, is currently in clinical
trials for different types of cancer. Thus, the insights gained in the last years on both the
mechanism of action of APLs as antitumor agents, especially edelfosine, and the clinical
experience acquired with some of these compounds, particularly miltefosine and perifosine,
constitute an invaluable source of information for the putative use of APLs as antiparasitic
drugs, as well as for the development of novel APL-related compounds as antileishmanial
drugs. Very recently, edelfosine has been shown to be effective against different types of
Leishmania parasites in in vitro and in vivo studies, displaying a better profile than miltefosine
on the generation of drug resistance [30]. In addition, edelfosine exerts a potent anti-inflam‐
matory effect [46], which is of importance as several of the clinical signs of leishmaniasis are
due to an inflammatory response. In this regard, it is also worth mentioning that current
evidence suggests that Leishmania parasites are initially engulfed by neutrophils, a major
inflammatory cell type, and delivered to cytoplasmic neutrophil granules [47], where they
survive and retain infectivity, thus using neutrophils as transport vehicles before they enter
safely and silently their ultimate host cell, the macrophage [48, 49]. Increasing evidence
suggests that APLs are new promising oral leishmanicidal drugs that could act either as single
drugs or as combination therapy.
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The antileishmanial efficacy of miltefosine in T cell-deficient athymic mice infected with L.
donovani (25 mg/kg of body weight dissolved in a volume of 0.3 ml tap water, orally adminis‐
tered) was similar to that found in normal mice [50, 51]. These observations were extended in
T and B-cell deficient severe combined immunodeficiency (SCID) mice, where miltefosine
showed a similar effect to that detected in normal BALB/c mice [52]. These results raise the
possibility that miltefosine may be of interest as an initial oral treatment approach to the
growing problem of AIDS-associated visceral leishmaniasis in CD4 cell-depleted patients [53].
Currently, miltefosine is the only APL in the market for the treatment of leishmaniasis, but
edelfosine and perifosine show promising and potent anti-Leishmania activity both in vitro and
in vivo [30, 54, 55], warranting further studies for their putative clinical use in the future. The
mechanism of action of miltefosine is not properly understood, but a clear correlation between
the accumulation of the drug within the parasite and its toxic effects has already been described
[27], this notion being identical to that previously advanced for edelfosine in its antitumor
activity [32, 56-58], and therefore the ability of APLs to kill different Leishmania species and
cancer cells is critically dependent on the drug uptake.
4. Mechanism of action of miltefosine as a leishmanicidal drug
The studies directed to unravel the underlying mechanism of miltefosine as an antiparasitic
drug have followed to great extent the same trends previously reported and advanced in the
analysis of the molecular and cellular pathways involved in the antitumor action of APLs.
Thus, the insights generated from the antitumor action of APLs on cancer cells are being
extrapolated to the APL killing action on Leishmania parasites. In this regard, a stark example
lies in the direct induction of cell death by APLs in both tumor cells and Leishmania parasites.
Following the studies reported simultaneously in 1993 by Diomede’s group in Milan [59] and
Mollinedo’s group in Madrid [60], showing that the APL edelfosine induced apoptosis in a
wide variety of tumor cells, subsequent studies extended this proapoptotic activity against
cancer cells to other APLs, including miltefosine and perifosine [61, 62]. Later on in the new
millennium, a number of studies have started to unveil the underlying mechanisms, signaling
pathways and subcellular structures involved in the antitumor activity of APLs, including
reorganization of lipid raft membrane domains, death receptors and mitochondria [32, 34, 63,
64]. These studies have provided a conceptual framework for a better understanding of the
processes involved in the anti-Leishmania activity of APLs. Thus, two reports came out in 2004
showing that miltefosine induced a cell death process showing several features of metazoan
apoptosis in L. donovani promastigotes and amastigotes [65, 66], including cell shrinkage, DNA
fragmentation into oligonucleosome-sized fragments, and phosphatidylserine exposure.
Then, subsequent studies have reported the miltefosine-mediated induction of an apoptosis-
like cell death in promastigotes from different species of Leishmania promastigotes, including
L. amazonensis [67], L. infantum [68], L. tropica [69], L. major [69], L. panamensis and many others
[30]. The fact that an apoptosis-related process seems to be involved in the death of Leishma‐
nia parasites upon APL addition is further supported by the recent finding that tolerance to
undergo apoptosis-like cell death in Leishmania is linked to multidrug resistance within the
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parasite in vitro [70]. This raises the concern that cross-tolerance to drug-induced apoptosis-
like cell death, not only against a particular selective drug promoting resistance, but also
against additional drugs sharing a similar mode of killing, might lead to a facilitated emergence
of cross-resistance against other drugs that have different cellular targets but analogous ways
of killing [70]. However the mechanism by which APLs induce an apoptosis-like cell death in
Leishmania parasites remains to be fully elucidated.
One critical organelle that seems to be involved in the killing process in Leishmania is the
mitochondrion. Miltefosine treatment has been found to lead to loss of mitochondrial mem‐
brane potential and the release of cytochrome c with consequent activation of cellular proteases
in L. donovani promastigotes, even in arsenite-resistant L. donovani promastigotes displaying a
multidrug resistance phenotype and overexpressing Pgp-like protein [71]. The finding that
edelfosine-induced cell death in L. infantum promastigotes can be regulated by the ectopic
expression of the antiapoptotic and proapoptotic members of the Bcl-2 family of proteins Bcl-
XL and Hrk, which affect mitochondria-related processes, suggests that this process shows
certain similarities to apoptosis in eukaryotic cells and that mitochondria are involved in the
killing process [72]. Furthermore, miltefosine inhibits mitochondrial cytochrome c oxidase in
L. donovani promastigotes, and this enzyme was suggested to act as a target for this APL [73].
In this regard, cytochrome c oxidase has also been identified as a potential target of miltefosine
from a genomic library screen of the model yeast Saccharomyces cerevisiae [74]. Miltefosine
inhibited cytochrome c oxidase activity in a dose-dependent manner, and this inhibition most
likely contributed to the miltefosine-induced apoptosis-like cell death in S. cerevisiae [74].
Figure 2 depicts a schematic view for the antileishmanial activity of miltefosine based on
current data.
Miltefosine
Drug uptake (LdMT/LdRos3)
Mitochondria-mediated processes and signaling
Effects on lipid metabolism
Apoptosis-like cell death
Figure 2. Schematic view of the antileishmanial mechanism of action of miltefosine. See text for further details.
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5. Miltefosine effects on lipid metabolism
APLs, including miltefosine, have been found to interact with membrane lipids and affect lipid
metabolism [75-77], these actions having been suggested being involved in their mechanism
of action. In lipid monolayer studies, miltefosine molecules were inserted into the monolayer
of lipids as monomers until the critical micellar concentration, and a high condensation was
found between miltefosine and sterols showing a high affinity between miltefosine and sterols
[78]. However, miltefosine did not act as detergent disturbing membrane integrity [78].
Leishmania parasites have high levels of ether-phospholipids [79-83], and these are mainly
found in the glycosylphosphatidylinositol-anchored glycolipids and glycoproteins present on
the surface of the parasites [84-86]. Because edelfosine and other APLs are ether lipids, it could
be suggested that the biosynthesis of ether lipids occurring in the glycosomes of Leishmania
might be affected. Miltefosine and edelfosine did not affect enzymes involved in early steps
in ether lipid biosynthesis in L. mexicana promastigotes, including dihydroxyacetonephos‐
phate acyltransferase, sn-l-acyl-2-lyso-glycero-3-phosphocholine and sn-l-alkyl-2-lyso-glyc‐
ero-3-phosphocholine acyltransferases activities [87]. However, both miltefosine and
edelfosine affected the later metabolism of alkyl-phosphatidylcholine intermediates by
inhibiting the glycosomal located alkyl-specific-acyl-CoA acyltransferase in a dose-dependent
manner with an inhibitory concentration of 50 µM, thus suggesting these drugs can perturb
ether-lipid remodelling [87]. However, the fact that inhibition of alkyl-specific-acyl-CoA
acyltransferase required drug concentrations higher than those showing cytotoxicity to L.
mexicana (IC50, 14 µM and 18 µM for miltefosine and edelfosine, respectively) [87] challenges
the putative involvement of this pathway as the primary target of these drugs. In addition, the
role of glycosylphosphatidylinositols and ether phospholipids in the survival of Leishmania
amastigotes is questioned by the viability of L. major null mutants for alkyldihydroxyaceto‐
nephosphate synthase (ADS), the first committed step of ether lipid synthesis. These mutants
lacked all ether phospholipids, including plasmalogens, lipophosphoglycan (LPG), and
smaller glycosylphosphatidylinositols (GIPLs) [88].
Treatment of L. donovani promastigotes with 10 µM miltefosine significantly reduced the
phosphatidylcholine content and enhanced the phosphatidylethanolamine content in parasite
membranes, suggesting a partial inactivation of phosphatidylethanolamine-N-methyltrans‐
ferase [89]. Phospholipase D activity was not affected by miltefosine, whereas the enhancement
of the lysophosphatidylcholine content could be ascribed to phospholipase A2 activation. No
effect was observed in the fatty acid alkyl chain length or the fatty acid unsaturation rate upon
miltefosine treatment, whereas a two-fold increase was detected in the amount of cholesterol
within the membranes [89]. Because cholesterol is not biosynthesized by the Leishmania
parasite, but is taken from the external medium, it might be envisaged that miltefosine
promotes cholesterol uptake in promastigotes perhaps by the condensation effect between
miltefosine and cholesterol [78]. In contrast, a strong reduction of about two times in the C24
alkylated sterol content was detected in miltefosine-treated membranes, even though the level
of the final C24 sterol alkylating product, ergosterol, the predominant plasma membrane sterol
in fungi and Leishmania, was not changed [89].
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Interestingly, the content of unsaturated phospholipid alkyl chains was lower in miltefosine-
resistant parasite plasma membranes than in those of the wild type, suggesting a lower fluidity
of miltefosine-resistant parasite membranes, and rendering the miltefosine interaction with
the external monolayer of miltefosine-resistant parasites more difficult. Miltefosine-resistant
parasite membranes displayed a higher content of short alkyl chain fatty acids, suggesting a
partial inactivation of the fatty acid elongation enzyme system in miltefosine-resistant
parasites, and the C24-alkylated sterol content was halved in miltefosine-resistant parasites,
but this modification was not related to miltefosine sensitivity [90]. Thus, miltefosine resistance
affects three lipid biochemical pathways: fatty acid elongation, the desaturase system respon‐
sible for fatty acid alkyl chain unsaturation, and the C-24-alkylation of sterols. [90]. Because of
the differences detected in the lipid composition of miltefosine-treated Leishmania and
miltefosine-resistant parasites, it could be hypothesized that continuous in vitro drug pressure
affects the regulation of Leishmania lipid metabolism [89], but the real implication of these
actions on parasite killing remains a topic of much debate.
6. Drug resistance
A major hurdle in successful leishmanial chemotherapy is emergence of drug resistance.
Miltefosine, the first orally administrable anti-leishmanial drug, has shown the potential
against drug-resistant strains of Leishmania. However, at the same time the readiness in
generating miltefosine-resistant parasites in vitro in the laboratory [27-29] raises some concerns
about the life span for an efficient use of miltefosine. The major underlying mechanisms
involved in the generation of miltefosine-resistant parasites seem to reside in defective drug
uptake into the parasite and increased drug efflux. In addition, its long half-life (approximately
150 hours) [91] might facilitate the emergence of resistance.
L. donovani promastigotes resistant to up to 40 µM miltefosine have been generated in vitro in
the laboratory by continuous step-wise drug pressure, resulting in being 15-fold more resistant
to miltefosine than wild-type promastigotes [28]. A drastic reduction (>95%) in the ability of
resistant L. donovani promastigotes to internalize [14C]miltefosine was detected, whereas
binding of miltefosine to the plasma membrane and drug efflux from preloaded cells were
similar in both drug-sensitive and -resistant cells, and no metabolism of [14C]miltefosine was
evident in either sensitive and resistant cells [92]. This miltefosine uptake was temperature
and energy dependent and sensitive to the thiol-reactive agent N-ethylmaleimide [92].
Resistant parasites were also unable to take up other short-chain phospholipid analogs,
independently of their polar head group, even though endocytosis remained unaltered [92].
The underlying basis for the generation of drug-resistant L. donovani promastigotes turned out
to be a decrease in the uptake of miltefosine mediated by the plasma membrane P-type
transporter L. donovani miltefosine transporter (LdMT) from the aminophospholipid translo‐
case subfamily and by LdRos3 [93, 94]. LdMT is an inward-directed lipid translocase belonging
to the P4 subfamily of P-type ATPases, which comprises lipid flippases that catalyze the
translocation of phospholipids from the exoplasmic to the cytosolic leaflet of cell membranes;
and LdRos3 is a non-catalytic subunit of LdMT that belongs to the CDC50/Lem3 family, which
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includes proteins proposed as likely beta subunits for P4-ATPases [93, 94]. LdMT and LdRos3
proteins are primarily localized to the Leishmania plasma membrane and required for the rapid
intracellular uptake of miltefosine and additional related choline-bearing lipids. Likewise, in
the budding yeast S. cerevisiae, members of the two protein families have been found to form
stable transporter complexes that function in the translocation of phospholipids from the
exoplasmic to the cytoplasmic leaflet of cellular membranes [95, 96]. Despite both LdMT and
LdRos3 normally localize to the plasma membrane, they are retained at the endoplasmic
reticulum in the absence of the other protein or in the presence of inactivating point mutations
in LdMT [94]. Both LdMT and the Cdc50-like protein LdRos3 form a stable complex that plays
an essential role in maintaining phospholipid asymmetry in the parasite plasma membrane
[97], and constitute part of the same translocation machinery that determines flippase activity,
responsible for miltefosine uptake, as well as miltefosine sensitivity in Leishmania [94]. Loss of
either LdMT or LdRos3 blocks ATP-dependent transport of NBD-labeled phosphatidyletha‐
nolamine and phosphatidylcholine from the outer to the inner plasma membrane leaflet in L.
donovani promastigotes and results in an increased cell surface exposure of endogenous
phosphatidylethanolamine, whereas infectivity was not compromised [97]. A promastigote
line, M-mutR, that shows mutations in LdMT, thus leading to defective miltefosine internali‐
zation, is infective to macrophages in vitro and in BALB/c mice in vivo, and displays a good
correlation of in vitro resistance between promastigotes and intracellular amastigotes [29]. The
fact that M-mutR parasites retain the resistant phenotype in vivo indicate that miltefosine-
resistant L. donovani promastigotes transform to miltefosine-resistant amastigotes [29]. It was
also observed no cross-resistance to other antileishmanial drugs in M-mutR amastigotes [29].
Some clinical studies have suggested, as indicated above, that miltefosine shows significantly
less efficiency against the cutaneous and mucocutaneous leishmaniasis caused by L. brazilien‐
sis parasites, mainly due to their inability to internalize the drug because of the low expression
levels of the beta subunit LbRos3 [98]. Overexpression of LbRos3 induced increased miltefo‐
sine sensitivity in both L. braziliensis promastigotes and intracellular amastigotes, further
supporting the notion that miltefosine uptake is a major event in determining miltefosine
antileishmanial potency [98]. Miltefosine-resistant promastigotes, displaying cross-resistance
to the ether lipid edelfosine, but not to the standard anti-leishmanial drugs, shows no ampli‐
fication of specific genes, including the multidrug resistance P-glycoprotein gene, and
resistance has been found to be stable up to 12 weeks in drug-free culture medium [28].
The evidence gathered so far has shown that reduced miltefosine incorporation has always
led to a resistant phenotype. This lower accumulation of miltefosine can be achieved by two
processes: a) a decrease in drug uptake, rendered by inactivation of any one of the two proteins
responsible for the miltefosine uptake, namely LdMT and its beta subunit LdRos3; b) an
increase in drug efflux, mediated by the overexpression of the ABC transporter P-glycoprotein
[27]. Thus, in addition to a flaw in the uptake of miltefosine as stated above, an increased efflux
of miltefosine has also been implicated in miltefosine resistance. A multidrug resistance (MDR)
L. tropica line overexpressing a P-glycoprotein-like transporter was found to display significant
cross-resistance to the ALP miltefosine and edelfosine, with resistant indices of 9.2- and 7.1-
fold, respectively [99]. This resistance was mediated through overexpression of an ABC
transporter, namely the Leishmania P-glycoprotein-like transporter (Leishmania ABCB1 or
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LtrMDR1) [99, 100]. ATP-binding cassette (ABC) transporters constitute one of the largest and
most conserved protein families and have been considered major players in drug resistance
during the treatment of cancer and infectious diseases. Interestingly, sesquiterpene C-3
completely sensitizes MDR parasites to APLs, acting as an inhibitor of LtrMDR1 [99]. In
addition, overexpression of two Leishmania-specific ABC subfamily G (ABCG)-like transport‐
ers localized at the plasma membrane of Leishmania protozoan parasites, LiABCG6 and
LiABCG4 half-transporters, conferred resistance to APLs in Leishmania parasites and S.
cerevisiae [101, 102]. Overexpression of LiABCG6 not only leads to miltefosine resistance in
vitro, but also to the antileishmanial oral drug 8-aminoquinoline analog sitamaquine [102].
Additional genes associated with miltefosine resistance have been identified by generating L.
major promastigote mutants highly resistant to miltefosine (80-100 µM) in a step-by-step
manner and subsequent analysis of the short-read whole genome sequencing [103]. In addition
to the previously described P-type ATPase involved in phospholipid translocation, another
new gene coding for pyridoxal kinase, involved in the formation of pyridoxal-5’-phophate
(active vitamin B6), has been implicated in miltefosine susceptibility [103]. Following this
genetic approach, it was clear the polyclonal nature of a resistant population with varying
susceptibilities and genotypes, indicating that miltefosine resistance can be genetically and
phenotypically highly heterogeneous [103].
7. Effects of APLs on the immune system
Even though miltefosine retains its antiparasitic activity against Leishmania infection in
immunodeficient SCID mice, leading to similar levels of activity in both SCID and BALB/c
mouse-L. donovani models [52], the immunomodulatory properties of miltefosine have been
proposed as an additional factor to its antileishmanial action [104]. Thus, miltefosine’s
antileishmanial function has been reported to be significantly compromised in interferon-
gamma (IFNγ)-deficient macrophages, suggesting the importance of endogenous IFNγ in the
miltefosine-induced antileishmanial functions of macrophages. IFNγ responsiveness is
reduced in L. donovani-infected macrophages but is significantly restored by miltefosine, as it
induces IFNγ, enhances IFNγ receptors, and IFNγ induces STAT-1 phosphorylation but
reduces activation of SHP-1, the phosphatase implicated in the downregulation of STAT-1
phosphorylation [104]. L. donovani-infected macrophages induced Th2 response, but miltefo‐
sine treatment reversed the response to Th1-type [104].
Miltefosine is able to form stable multilamellar vesicles (MLVs liposomes) to deliver the APL
to monocytes/macrophages. Both micellar and liposomal miltefosine have been found to
interact with human monocytes and upregulate specific adhesion molecules, including
intracellular adhesion molecule-1 and class 1 major histocompatibility complex (MHC-1)
antigen in a dose-dependent manner in U937 cells [105], used as a cell line model system to
study human monocytes. These actions could be involved in the initial steps of miltefosine-
mediated recruitment of macrophages [105]. Miltefosine, better in liposomal than in free
(micellar) form, has also been reported to induce an increase in tumor necrosis factor (TNF)
Alkylphospholipids and Leishmaniasis
http://dx.doi.org/10.5772/58318
451
release and nitric oxide (NO) generation after in vitro co-culture of mouse peritoneal macro‐
phages or U937 cells with lipopolysaccharide (LPS) [106-108]. Miltefosine has also been
reported to enhance the immune response of IL-2-stimulated mononuclear cells resulting in
granulocyte-macrophage colony-stimulating factor (GM-CSF) and IFNγ gene expression and
IFNγ secretion [109].
However, recent studies on the effects of miltefosine on dendritic cells (DC) in L. major infection
have challenged the putative role of the immunomodulatory action of miltefosine on its
antiparasitic action, and suggest that miltefosine functions independently of the immune
system, mostly through direct toxicity against the Leishmania parasite [110]. DC are critical for
initiation of protective immunity against Leishmania through induction of Th1 immunity via
interleukin 12 (IL-12), and when co-cultured with miltefosine for 4 days, most of the in vitro-
infected DC were free of parasites. However, miltefosine treatment did not influence DC
maturation (upregulation of major histocompatibility complex II [MHC II] or co-stimulatory
molecules, e.g., CD40, CD54, and CD86), did not significantly alter cytokine release (IL-12,
tumor necrosis factor alpha [TNF-α], or IL-10), antigen presentation, or NO production [110].
8. Canine leishmaniasis
Miltefosine is marketed as Milteforan® (Virbac, Carros, France) for the treatment of canine
visceral leishmaniasis that is the result of infection with L. infantum in the Old World and L.
chagasi in the New World. These two Leishmania species are considered sibling and indistin‐
guishable species, and several genetic studies have shown evidence for the synonym of L.
infantum and L. chagasi, and suggest the introduction of L. infantum from Southwest Europe
into the New World in recent history [111-114]. Thus, L. infantum (Old World) and L. chagasi
(New World) belong to the same species, and therefore L. chagasi has been synonymized with
L. infantum. Dogs are considered the primary reservoir hosts of L. infantum/chagasi, and
infection of dogs with L. infantum/chagasi involves cells of the lymphatic series resulting in
visceralization of infection. The domestic dog seems to be a main reservoir for human visceral
leishmaniasis, rendering canine disease control a critical issue. Unfortunately efforts to control
leishmaniasis in dogs have been largely unsuccessful so far. Oral administration of miltefosine
at a dose of 2 mg/kg body weight once a day for 28 days leads to significant reduction of parasite
loads and clinical symptoms, whereas adverse reactions were not serious and observed in less
that 12% of the dogs, the most frequent one being vomiting, which was transient, self-limiting,
and reversible [115-117]. Leishmania DNA quantification by real-time PCR has shown that
miltefosine treatment of dogs leads to a drastic and progressive reduction of parasite load in
lymph node aspirates, but does not suppress the parasite in lymph nodes [118]. Miró et al.
[119] has shown that the treatment of miltefosine-allopurinol combination therapy (2 mg/kg
miltefosine orally once daily for 28 days and 10 mg/kg of allopurinol orally twice daily for 7
months) behaved similarly to the current reference combination therapy, namely meglumine
antimoniate-allopurinol (50 mg/kg of meglumine antimoniate sub-cutaneously twice daily for
28 days and 10 mg/kg of allopurinol orally twice daily for 7 months), in promoting a significant
reduction in total clinical score and parasite load over the 7-month study period. These
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observations together with the lack of effect on renal and hepatic parameters and adverse
reactions suggests that miltefosine, in combination with allopurinol, might offer a safe and
effective alternative treatment option for canine leishmaniasis compared to the reference
therapy [119]. A recent study [117], where dogs naturally infected with L. infantum/chagasi were
treated with miltefosine using different therapeutic regimens, has shown that after treatment
and during the following 24 months, there was progressive clinical improvement and complete
recovery in 50% (7/14) of the treated animals. There was a decrease in the smear positivity of
the bone marrow after treatment, and there was also a gradual and constant decrease in
positive cultures at the end of the follow-up period. However, the PCR detection of parasite
DNA remained positive, and the animals presented a significant increase in parasite load 6
months after treatment. Thus, the fact that the improvement in the clinical symptoms is not
followed by total parasitological clearance, raises some doubts about the use of this drug in
endemic areas where the dogs are involved in the maintenance of the parasite cycle.
9. Conclusions
At present the control of protozoan parasite Leishmania infections relies primarily on chemo‐
therapy, but the armoury of drugs available for treating Leishmania infections is rather limited
and includes a few drugs with unknown cellular targets and unclear mode of action. These
drugs include pentavalent antimonials, pentamidine, amphotericin B, miltefosine, paromo‐
mycin, fluconazole, allopurinol, and few other drugs at various stages of their development
process. The recent inclusion of miltefosine as a new antileishmanial drug has been a break‐
through in the treatment of leishmaniasis, as it constituted the first effective oral drug, thus
facilitating medical access and making treatment more accessible to rural and remote areas.
Interestingly, miltefosine belongs to a family of lipid compounds collectively known as APLs,
some of them showing also interesting and promising antileishmanial activities in addition to
their well known antitumor action. Thus, additional APLs or APL-related compounds might
be of interest to identify novel drugs to combat Leishmania infections both in humans and
animals, especially in dogs as major reservoirs for human visceral leishmaniasis (L. infantum/
chagasi). Identification of the death signaling pathways activated in miltefosine-sensitive
parasites will be essential for a better understanding of the molecular mechanisms of action
and resistance in these parasites. In this regard, the knowledge acquired for the antitumor
action of APLs is being and will be of further aid to unveil the mode of action of miltefosine
and putative additional APLs with potent antileishmanial activities. Furthemore, elucidation
of the molecular mechanisms underlying miltefosine- and APL-mediated cell death will
facilitate the design of new therapeutic strategies against Leishmania parasites. The proneness
to generate in vitro resistance to miltefosine raises some concerns about its putative life span
in clinical use, thus favoring research on additional APLs that could improve the current
antileishmanial features of miltefosine as well as on combination therapy regimens. APLs have
shown themselves as potent antileishmanial drugs, and current evidence warrants further
research on these promising lipid drugs that could make a difference in the clinical setting and
medical care of leishmaniasis.
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